Asciminib for chronic myeloid leukemia after prior treatments
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well asciminib works in real-world patients with chronic myeloid leukemia who have already tried at least one other treatment. It aims to see how effective and safe it is in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic myeloid leukemia in the chronic phase.
- You have already had at least one other treatment for your leukemia.
- Your doctor has prescribed asciminib as part of your usual care.
- You are willing and able to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study looks at how safe and effective asciminib is for young adults with chronic myeloid leukemia (CML) in the Gulf region. It uses existing medical records to gather information, so no extra visits are needed.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.